The approval is the second for an RSV monoclonal antibody preventive for infants.
Estimates varied from 2008 through 2018, with RSV-associated antibiotic prescribing exceeding 10% in peak RSV years and flu-associated prescribing exceeding 20% in peak flu years.
A retrospective analysis of hospitalized VA patients finds that prior flu or RSV infection more than doubled the odds of subsequent Streptococcus pneumoniae infection.
The WHO is recommending use of a maternal RSV vaccine and the monoclonal antibody nirsevimab to protect infants against the virus.
Costs varied across 5 European countries, driven primarily by repeated primary care visits and parental work absences.
A total of 11% of RSV patients experienced a cardiac event, abnormal heart rhythm, heart failure, or ischemic heart disease.
A separate study found that 72% of infants were protected against RSV through maternal vaccination or infant receipt of nirsevimab in 2023-24.
Wastewater levels for COVID-19 are low, while for influenza A and RSV they are very low.
For patients with weakened immune systems, effectiveness was lower, at 67% for patients aged 60 to 74 years to 73% for those older than 75.
The 10 new flu-related deaths in children bring the season's total to 226, the most since 2009-10.
